ENP.AX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: July 31, 2025
Report Source: 2025 2nd Quarter Report
Entropy Neurodynamics Ltd. Stock Analysis ENP.AX
Entropy Neurodynamics Ltd. is a clinical-stage biotechnology company, which engages in investing in biopharmaceutical drug development. The Company’s lead program, TRP-8803, is a proprietary formulation of IV infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The firm has completed a Phase 2a clinical trial for the treatment of binge eating disorder and for the treatment of fibromyalgia. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications.
Read More Entropy Neurodynamics Ltd (ENP.AX) Chart
Key Statistics of Entropy Neurodynamics Ltd (ENP.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.04Volume
2.79MP/E Ratio (TTM)
-52 Week Range
Market Cap
60.38MAvg. Volume
-Dividend Yield
-Financial Metrics & Statements of Entropy Neurodynamics Ltd (ENP.AX)
FAQ's for Entropy Neurodynamics Ltd (ENP.AX)
- According to Musaffa’s Shariah screening methodology, Entropy Neurodynamics Ltd (ENP.AX) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.